Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors
Preventive Effect of EGF Cream for Cutaneous Adverse Event of EGFR Inhibitors
The purpose of this study is to evaluate the preventive efficacy of topical EGF cream for
 dermatologic adverse events related to EGFR inhibitors.
Epidermal growth factor receptor(EGFR) is involved in cell proliferation and is overexpressed
 or abnormally activated in malignant tumors originating from the colon, breast, ovary,
 pancreas, and lung. EGFR tyrosine kinase inhibitor(TKI), gefitinib, erlotinib, and afatinib
 have been for the treatment of cancer associated with EGFR gene mutation. In addition,
 monoclonal antibodies to EGFR, such as cetuximab and panitumumab, have been used as a
 chemotherapy for rectal cancer without ras gene mutation and advanced head and neck cancer.

 The incidence of cutaneous toxicity of EGFR inhibitors is reported to be 75-80%. Clinical
 features include acneform folliculitis, xerosis, paronychia, and itching. Of these, about 10%
 of patients with Grade 3 or greater have a detrimental effect on quality of life and
 adherence to treatment, resulting in impaired therapeutic results.

 There have been many attempts to prevent or treat such skin toxicity. However, there has been
 no scientifically proven treatment until now.

 There is a growing interest in the role of EGF emulsifiers in the treatment of skin adverse
 effects of EGFR inhibitors, as a result of studies that improve acne significantly compared
 to placebo.

 The purpose of this study is to evaluate the preventive efficacy of EGF cream in the
 treatment of skin adverse effects in patients with malignant tumors treated with EGFR
 inhibitor (TKI or monoclonal antibody).
Inclusion Criteria:

 -  Over 20 years old

 -  Patients scheduled to receive EGFR inhibitors (gefitinib, erlotinib, afatinib,
 cetuximab, etc.) as malignant tumors

 -  Patients who can understand and follow the protocol

 -  Patients who spontaneously agreed to the study

 Exclusion Criteria:

 -  Patients with a history of antibiotic treatment, local and systemic steroid therapy
 within 4 weeks of other skin disorders

 -  Patients with existing acne history

 -  Breastfeeding or pregnant women

 -  Patients who are deemed unsuitable for the examination by the researcher's judgment